Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardian Pharmacy Services (GRDN) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $9.6 million.

  • Guardian Pharmacy Services' Income towards Parent Company rose 10906.57% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 15787.02%. This contributed to the annual value of -$71.0 million for FY2024, which is 28831.65% down from last year.
  • Per Guardian Pharmacy Services' latest filing, its Income towards Parent Company stood at $9.6 million for Q3 2025, which was up 10906.57% from $8.8 million recorded in Q2 2025.
  • Over the past 5 years, Guardian Pharmacy Services' Income towards Parent Company peaked at $15.8 million during Q2 2024, and registered a low of -$105.8 million during Q3 2024.
  • Its 3-year average for Income towards Parent Company is -$4.0 million, with a median of $9.3 million in 2025.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 141275.2% in 2024, then skyrocketed by 10906.57% in 2025.
  • Over the past 3 years, Guardian Pharmacy Services' Income towards Parent Company (Quarter) stood at $14.6 million in 2023, then fell by 18.67% to $11.8 million in 2024, then decreased by 18.98% to $9.6 million in 2025.
  • Its Income towards Parent Company stands at $9.6 million for Q3 2025, versus $8.8 million for Q2 2025 and $9.3 million for Q1 2025.